NCT02001935已完成不适用
Association Between CytochromeP4501A2(CYP1A2) and CytochromeP4502E1(CYP2E1) Gene Polymorphisms and Metabolism of Theophylline in a Chinese Population
Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2013年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- Theophylline clearance
研究概览
简要总结
The aim of this study is to determine whether common CYP1A2 and CYP2E1 gene polymorphisms effect metabolism of theophylline in chronic obstructive pulmonary disease patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18-75 years,COPD patients, male or female;
- •regularly visiting our hospital;
- •taking a sustained-release preparation of theophylline continuously for at least 2 weeks
排除标准
- •patients with renal or hepatic dysfunction;
- •patients with congestive heart failure;
- •patients with hypothyroidism or hyperthyroidism;
- •patients currently taking drugs likely to affect theophylline metabolism or who had taken such drugs in the preceding week;
- •patients with extreme obesity
- •patients with very severe Chronic Obstructive Pulmonary Disease(COPD)
研究组 & 干预措施
theophylline
Other
干预措施: theophylline (Drug)
结局指标
主要结局
Theophylline clearance
时间窗: Blood samples will be taken after receiving oral thoephylline for 14 days
Theophylline and it's metabolite(1,3-dimethyluric) blood concentration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of TheophyllineChronic Obstructive Pulmonary DiseaseNCT03015090XiaoGuang Zou110
已完成
1 期
Caffeine and anaerobic exercise performance: an exploration of caffeine’s effects on performance in young men and the influence of genotype on the variation in responsesExercise performanceMusculoskeletal - Normal musculoskeletal and cartilage development and functionMetabolic and Endocrine - Normal metabolism and endocrine development and functionACTRN12619000885190Victoria University22
已完成
1 期
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, FluvoxamineHealthy VolunteersNCT01540500Vanda Pharmaceuticals24
已完成
不适用
Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal SymptomsAlcohol WithdrawalNCT05563350University Hospital Bispebjerg and Frederiksberg26
已完成
不适用
Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During ClarithromycinDrug InteractionsNCT01425229Gerd Mikus16